ATE396969T1 - 3,6-disubstituierte azabicyclo (3.1.0)hexanderivate, die sich als muscarinrezeptorantagonisten eignen - Google Patents

3,6-disubstituierte azabicyclo (3.1.0)hexanderivate, die sich als muscarinrezeptorantagonisten eignen

Info

Publication number
ATE396969T1
ATE396969T1 AT02751482T AT02751482T ATE396969T1 AT E396969 T1 ATE396969 T1 AT E396969T1 AT 02751482 T AT02751482 T AT 02751482T AT 02751482 T AT02751482 T AT 02751482T AT E396969 T1 ATE396969 T1 AT E396969T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
compounds
muscarine receptor
hexane derivatives
disubstituted azabicyclo
Prior art date
Application number
AT02751482T
Other languages
English (en)
Inventor
Anita Mehta
Arundutt Silamkoti
Kirandeep Kaur
Jang Bahadur Gupta
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Application granted granted Critical
Publication of ATE396969T1 publication Critical patent/ATE396969T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02751482T 2002-07-31 2002-07-31 3,6-disubstituierte azabicyclo (3.1.0)hexanderivate, die sich als muscarinrezeptorantagonisten eignen ATE396969T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/002984 WO2004014853A1 (en) 2002-07-31 2002-07-31 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
ATE396969T1 true ATE396969T1 (de) 2008-06-15

Family

ID=31503897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751482T ATE396969T1 (de) 2002-07-31 2002-07-31 3,6-disubstituierte azabicyclo (3.1.0)hexanderivate, die sich als muscarinrezeptorantagonisten eignen

Country Status (7)

Country Link
US (1) US7265147B2 (de)
EP (1) EP1546098B1 (de)
AT (1) ATE396969T1 (de)
AU (1) AU2002368152A1 (de)
DE (1) DE60226906D1 (de)
HK (1) HK1079787A1 (de)
WO (1) WO2004014853A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537584A (en) 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
AU2003214520A1 (en) 2003-04-09 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100436414C (zh) 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
EP1746998A1 (de) * 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Kombinationstherapie für symptome der unteren harnwege
EP1934184A1 (de) 2005-10-05 2008-06-25 Ranbaxy Laboratories, Ltd. 3 -azabicyclooctanderivate als antagonisten des muscarinrezeptors
AU2006334107A1 (en) 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US20090137623A1 (en) 2005-12-30 2009-05-28 Naresh Kumar Muscarinic receptor antagonists
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
JP5815542B2 (ja) * 2009-10-29 2015-11-17 ヤンセン ファーマシューティカ エヌ．ベー． Ｄｐｐ−１阻害剤として有用なアルキニル誘導体
CA2796877A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
ES2619829T3 (es) 2011-11-18 2017-06-27 Heptares Therapeutics Limited Agonistas del receptor muscarínico M1
CN104177284B (zh) * 2014-08-01 2016-08-24 常州大学 合成3-氮杂二环[3,1,0]己基-1-甲醛的方法
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (de) * 1960-07-26
US4183857A (en) * 1978-07-06 1980-01-15 Shell Oil Company 3-Benzyl-3-azabicyclo(3.1.0)hexane-2,4-dione
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
GB8906166D0 (en) 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5281601A (en) * 1989-12-12 1994-01-25 Pfizer Inc. Muscarinic receptor antagonists
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
FI100051B (fi) 1992-02-18 1997-09-15 Favorit Oy Kompostori
JP3429338B2 (ja) 1992-07-27 2003-07-22 杏林製薬株式会社 新規なアリールグリシンアミド誘導体及びその製造法
JPH06135958A (ja) 1992-10-28 1994-05-17 Tanabe Seiyaku Co Ltd ベンゾシクロヘプテン誘導体及びその製法
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
KR19990008109A (ko) 1995-04-28 1999-01-25 나가사까 겐지로 1,4-이치환 피페리딘 유도체
CA2179574A1 (en) * 1995-06-26 1996-12-27 Tomomi Okada Substituted piperidine derivative and medicine comprising the same
WO1997013766A1 (fr) * 1995-10-13 1997-04-17 Banyu Pharmaceutical Co., Ltd. Derives heteroaromatiques substitues
AU2793197A (en) 1996-05-31 1998-01-05 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
GB9620049D0 (en) * 1996-09-26 1996-11-13 Hayles J R Repellent formulations
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy

Also Published As

Publication number Publication date
AU2002368152A1 (en) 2004-02-25
EP1546098B1 (de) 2008-05-28
WO2004014853A1 (en) 2004-02-19
HK1079787A1 (zh) 2006-04-13
US7265147B2 (en) 2007-09-04
EP1546098A1 (de) 2005-06-29
DE60226906D1 (de) 2008-07-10
EP1546098A4 (de) 2006-08-23
US20060122253A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
HK1079787A1 (zh) 用作毒蕈碱受體拮抗劑的3，6-二取代的氮雜雙環[3．1．0]己烷衍生物
WO2004004629A3 (en) 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1796678A4 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
IL182317A0 (en) Cgrp receptor antagonists
WO2004091514A3 (en) Cgrp receptor antagonists
GEP20084519B (en) 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors
HK1085724A1 (en) 3,6-disubstituted azabicyclo 3.1.0-hexane derivatives as muscarinic receptor antagonists
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
WO2006035282A3 (en) Muscarinic receptor antagonists
EP1398029A8 (de) 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
WO2004067510A8 (en) 3,6-disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
ATE386738T1 (de) Flavaxat-derivate als muscarin-rezeptor antagonisten
ATE362364T1 (de) Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
WO2006018708A3 (en) Pyrrolidine derivatives as muscarinic receptor antagonists
WO2006032994A3 (en) Muscarinic receptor antagonists
ATE383343T1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
ATE419246T1 (de) Als antagonisten des muscarinrezeptors geeignete xanthinderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties